Research Protections Office (RPO)

RPO Educational Offerings

The RPO regularly offers educational sessions for faculty researchers.

Upcoming Educational Offerings

Help Sessions

Body

Check back regularly to ensure you know when the educational offering is taking place. 

Members from RPO, OACM, and EHS are collaborating to provide one-stop support on the following dates and times to assist researchers and research personnel on the following:

  • Those looking to submit or have submitted a new IACUC protocol/amendment, IBC registration/amendment, or CSC registration/amendment in UVMClick,
  • Those responding to the Committee's clarifications,
  • Those with general questions or comments for RPO, OACM, or EHS,
  • Those with general questions or those who need assistance with UVMClick, VOS, or SciShield.

Please bring your questions, comments, and concerns! 

Wednesday, January 28, 2026 from 9:00AM-11:00AM in HSRF 400
Wednesday, February 25, 2026 from 9:00AM-11:00AM in HSRF 400
Wednesday, March 25, 2026 from 9:00AM-11:00AM in HSRF 400
Wednesday, April 29, 2026 from 9:00AM-11:00AM in HSRF 400
Wednesday, May 27, 2026 from 9:00AM-11:00AM in HSRF 400
Wednesday, June 24, 2026 from 9:00AM-11:00AM in HSRF 400

Previous Educational Offerings

Wed May 01 2024

Body

“Institutional Review Board (IRB) and the Protocol Review and Monitoring Committee (PRMC) – What’s the Difference?”

1:00pm - 1:00pm 

HSRF Room 300

For researchers who intend to recruit cancer patients from cancer-focused clinics, or the primary aim of the study is related to cancer (the diagnosis, screening, treatment, or prevention of cancer; risk factors associated with the development or survivorship of cancer; data and/or biological specimens from cancer patients) this session will review the fundamental differences and regulatory mandates required for each committee’s reviews.


Revised date/time - Wednesday May 1, 2024

1:00- 2:00 HSRF Room 300

Presented by: Melanie Locher, B.S., IRB Director & Christa Varnadoe-Rothman, DNP, MSN, AGNP-C, OCN, CCRP, Director, Cancer Clinical Trials